William Avery
21 works · 2,476 citations · h-index 10
Top works
- Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability
- Synergistic drug combinations tend to improve therapeutically relevant selectivity
- Definitive Hematopoiesis Requires the Mixed-Lineage Leukemia Gene
- Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity
- Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug
- The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action
- Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
- Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
- M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease
- Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.
- Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.
- Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
- THU0057 Targeting the Neonatal FC Receptor (FCRN) to Mediate Autoantibody Clearance in IgG-Driven Autoimmune Disease
- Preclinical Evaluation of CRx-501, a Potent Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma
- Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats
- M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer.
- Ultra long‐acting oral therapies for Alzheimer's: Proof of principle
- Nipocalimab a High Affinity, Immunoselective Clinical FcRn Blocker with Unique Properties: Observations from Non-clinical and Clinical Studies (P4-14.008)
- Synergistic Activity of Adenosine A2A and Beta-2 Adrenergic Receptor Agonists in Myeloma Cells in the Context of Tumor-Stromal Interactions
- Abstract 1524: M402, a novel heparan sulfate mimetic, inhibits pancreatic tumor growth and desmoplasia potentially via sonic hedgehog signaling in an orthotopic mouse model